Use of intravenous gamma globulin to passively immunize high-risk children against respiratory syncytial virus: safety and pharmacokinetics. The RSVIG Study Group.

Infants with cardiopulmonary disease develop severe illness from respiratory syncytial virus (RSV) infection. Safety, feasibility, and pharmacokinetics of intravenous gamma globulin (IVIG) to prevent RSV illness were studied in 23 high-risk infants in a phase I trial. IVIG with an RSV neutralizing a...

ver descrição completa

Detalhes bibliográficos

Publicado no:	Antimicrob Agents Chemother
Principais autores:	Groothuis, J R, Levin, M J, Rodriguez, W, Hall, C B, Long, C E, Kim, H W, Lauer, B A, Hemming, V G
Formato:	Artigo
Idioma:	Inglês
Publicado em:	American Society for Microbiology (ASM) 1991
Assuntos:	Research Article
Acesso em linha:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC245192/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/1718213/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.35.7.1469
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!